InnoMed PredTox

Jump to navigation Jump to search
InnoMed PredTox
Innovative Medicines for Europe - Predictive Toxicology
Keywords Toxicogenomics, Drug development, Pre-clinical development
Funding agency European Commission
Project type Integrated Project
Reference FP6-518170
Objective Assess the value of combining results from omics technologies together with the results from more conventional toxicology methods for more informed decision making in preclinical safety evaluation
Participants EFPIA (coordinator),

EFPIA Companies
Bayer Schering Pharma
Johnson and Johnson
Merck Serono
Novo Nordisk

University of Würzburg
University College Dublin
Hacettepe University

Technology Providers

Budget Overall: 8 Mio. EUR


Duration 1 October 2005 - 31 January 2009
Web site

WikiDoc Resources for InnoMed PredTox


Most recent articles on InnoMed PredTox

Most cited articles on InnoMed PredTox

Review articles on InnoMed PredTox

Articles on InnoMed PredTox in N Eng J Med, Lancet, BMJ


Powerpoint slides on InnoMed PredTox

Images of InnoMed PredTox

Photos of InnoMed PredTox

Podcasts & MP3s on InnoMed PredTox

Videos on InnoMed PredTox

Evidence Based Medicine

Cochrane Collaboration on InnoMed PredTox

Bandolier on InnoMed PredTox

TRIP on InnoMed PredTox

Clinical Trials

Ongoing Trials on InnoMed PredTox at Clinical

Trial results on InnoMed PredTox

Clinical Trials on InnoMed PredTox at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on InnoMed PredTox

NICE Guidance on InnoMed PredTox


FDA on InnoMed PredTox

CDC on InnoMed PredTox


Books on InnoMed PredTox


InnoMed PredTox in the news

Be alerted to news on InnoMed PredTox

News trends on InnoMed PredTox


Blogs on InnoMed PredTox


Definitions of InnoMed PredTox

Patient Resources / Community

Patient resources on InnoMed PredTox

Discussion groups on InnoMed PredTox

Patient Handouts on InnoMed PredTox

Directions to Hospitals Treating InnoMed PredTox

Risk calculators and risk factors for InnoMed PredTox

Healthcare Provider Resources

Symptoms of InnoMed PredTox

Causes & Risk Factors for InnoMed PredTox

Diagnostic studies for InnoMed PredTox

Treatment of InnoMed PredTox

Continuing Medical Education (CME)

CME Programs on InnoMed PredTox


InnoMed PredTox en Espanol

InnoMed PredTox en Francais


InnoMed PredTox in the Marketplace

Patents on InnoMed PredTox

Experimental / Informatics

List of terms related to InnoMed PredTox

InnoMed PredTox is a joint Industry and European Commission collaboration to improve drug safety. The consortium is composed of 15 research groups from 12 pharmaceutical companies, three academic institutions and two technology providers. The goal of InnoMed PredTox is to assess the value of combining results from omics technologies together with the results from more conventional toxicology methods for more informed decision making in preclinical safety evaluation.

The project was initiated in October 2005 with a term of 40 month. It receives funding as an Integrated Project under the Sixth Framework Programme. The project had been set up jointly by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Commission as a pilot project for the subsequent design of the Innovative Medicines Initiative[1][2]

As part of InnoMed PredTox the partners ran a series of regular 14 days toxicological studies in rats with daily dosing. The compounds had been selected representing compounds with promising drug-like properties but that had been terminated due to toxic effects on the liver and/or kidneys.

The project collected and jointly analysed transcriptomics, proteomics, metabonomics and conventional toxicological data on 14 failed drug candidates together with two reference compounds[3], troglitazone[4] and gentamicin[5]. As data integration across different data areas and technology platforms is considered a prerequisite to building a consistent standardised data schema for joint analysis[6] all project data are stored in a database[7] custom developed by Genedata.

Joint research activities like InnoMed PredTox are seen by the pharmaceutical industry as the most promising approach to increasing the number of generally accepted, measurable indicators biomarkers of toxic (side-) effects. In particular, as the consortia facilitate the efficient exchange of experience in this pre-competitive area of drug development and early involvement of regulatory authorities like the FDA and EMEA.[8]


Status: August 2008

Date Event
5 July 2005 Consortium Formation
1 October 2005 Official project start
28 November 2005 Selection of Study Compounds
7 April 2006 Start in vivo studies
10 October 2006 PredTox Database goes live
5 March 2007 Reporting of in vivo studies
9 July 2007 Reporting of Transcriptomics results
1 October 2007 Reporting of Proteomics results
14 January 2008 Formation of Expert Working Groups
21 July 2008 Reporting of individual integrated analyses per compound study
13 October 2008 Reporting of concluding study reports and discussion of project summary and conclusions


  1. IMI website by EFPIA [1]
  2. European Commission website [2]
  3. Mulrane et al., Exp Toxicol Pathol. 2008 Aug;60(4-5):235-45 [3]
  4. E. Troesken et al., Application of a Systems Toxicology Approach to Investigate Troglitazone Hepatotoxicity in the Rat, Abstract ID 675, The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 102, Number S-1, March 2008 [4] (slides)
  5. E. Com et al., Integrated Transcriptomic and Proteomic Evaluation of Gentamicin Nephrotoxicity in Rats, Abstract ID 676, The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 102, Number S-1, March 2008 [5] (slides)
  6. A.M. Richard, Chem Res Toxicol. 2006 Oct;19(10):1257-62[6]
  7. W.B. Mattes, Methods Mol Biol. 2008;460:221-38. [7]
  8. Hughes, Bethan (September 2008). "Industry concern over EU hepatotoxicity guidance". Nature Reviews Drug Discovery. 7: 719.

See also

External links

Template:WH Template:WS